Malignant brain tumors, such as glioblastoma and astrocytoma, are the most aggressive diffuse gliomas with a high grade (4) of malignancy in adults, leading to high mortality. The development of pharmacological approaches to drug delivery systems has led to increased effectiveness and reduced systemic toxicity of anticancer therapy. Delivery systems, such as implants, plates, gels, and micro- and nanoparticles, are used as carriers for anticancer substances, improving their solubility and biodistribution. These delivery systems affect the mechanism of drug action, reduce toxicity, Micro- and nanoparticles can penetrate physiological barriers of the body, including the blood-brain barrier (BBB). Due to changes in the microvascular system, they linger and accumulate in the area of pathology. Despite extensive data on delivery systems, only a few have undergone clinical trials and been adopted into clinical practice. For over 20 years, polymeric plates containing carmustine have been clinically used to treat malignant brain tumors. The search for safer and more effective forms of drug anti-tumor agents continues, as glioblastoma remains an incurable disease. Doxorubicin is a primary chemotherapy agent with proven efficacy, which is included in standard therapy for almost all tumor types. However, it is not used to treat central nervous system tumors, as it is believed that it does not cross the BBB. The polymers of lactic acid and glycolic acid (PLGA or PLG) are biocompatible and biodegradable. Standards for different tumor types where doxorubicin is used. We describe the mechanisms of action of polymeric and nanoparticle forms of chemotherapy drugs, the prospects of using PLGA polymers, and assess possible ways to deliver doxorubicin and other medications for brain tumors effectively.
Read full abstract